Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6421
    -0.0004 (-0.07%)
     

  • OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD

    2,406.70
    +8.70 (+0.36%)
     

  • Bitcoin AUD

    99,288.12
    +3,695.39 (+3.87%)
     

  • CMC Crypto 200

    1,369.11
    +56.48 (+4.31%)
     

  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     

  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Recent clinical trials on the treatment for Granulomatosis With Polyangiitis | DelveInsight

DelveInsight Business Research LLP
·4-min read

Approximately 2+ key companies are developing Granulomatosis with Polyangiitis therapies. The companies with Granulomatosis with Polyangiitis drug candidates in the mid to advanced stage (phase III and Phase II) include InflaRx GmbH and others.

Los Angeles, USA, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Recent clinical trials on the treatment for Granulomatosis With Polyangiitis | DelveInsight

Approximately 2+ key companies are developing Granulomatosis with Polyangiitis therapies. The companies with Granulomatosis with Polyangiitis drug candidates in the mid to advanced stage (phase III and Phase II) include InflaRx GmbH and others.

DelveInsight’s “Granulomatosis With Polyangiitis Pipeline Insight” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in the Granulomatosis With Polyangiitis pipeline landscapes. It comprises Granulomatosis With Polyangiitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Granulomatosis With Polyangiitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Granulomatosis With Polyangiitis pipeline products.

ADVERTISEMENT

Some of the key takeaways from the Granulomatosis With Polyangiitis Pipeline Report

  • Major companies such as InflaRx GmbH, Bristol-Myers Squibb, and others are developing potential drug candidates to improve the Granulomatosis With Polyangiitis treatment scenario.

  • In November 2021, ChemoCentryx announced that it had received a positive recommendation from European Medicines Agency's Committee for Medicinal Products for Human Use (“CHMP”) for its drug, Tavneos (avacopan), for the treatment of adult patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis).

Get an overview of pipeline landscape @ Granulomatosis With Polyangiitis Clinical Trials Analysis

Granulomatosis with Polyangiitis, formerly known as Wegener's granulomatosis, is an uncommon disorder that causes inflammation of the blood vessels in your nose, sinuses, throat, lungs and kidneys.

Granulomatosis With Polyangiitis Emerging Drugs

  • Abatacept: Bristol-Myers Squibb

Abatacept inhibits T cell activation, selectively blocking the specific binding of the CD80/CD86 receptor in APC to CD28 on T cells. It is currently in the phase III stage of development in collaboration with The Cleveland Clinic, Bristol-Myers Squibb, University of Pennsylvania, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

  • IFX-1 (Vilobilemab):InflaRx GmbH

InflaRx GmbH, in collaboration with Iqvia Pty Ltd, has resulted in the development of IFX-1 i, a monoclonal antibody specifically binding to the soluble human complement split product C5a and the resulting nearly complete blockade of C5a-induced biological effects. IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development and has, to date, completed three clinical phases II studies.

For further information, refer to the detailed report @ Granulomatosis With Polyangiitis Pipeline Therapeutics

Scope of Granulomatosis With Polyangiitis Pipeline Drug Insight

  • Coverage: Global

  • Major Players: 2+ Key Players

  • Prominent Players: InflaRx GmbH, Bristol-Myers Squibb, and many others.

  • Key Drugs Profiles: 2+ Products

  • Phases:

· Granulomatosis With Polyangiitis Therapies Late-stage (Phase III)
· Granulomatosis With Polyangiitis Therapies Mid-stage (Phase II)
· Granulomatosis With Polyangiitis Therapies Early-stage (Phase I)
· Granulomatosis With Polyangiitis Preclinical stage and Discovery candidates
· Discontinued and Inactive candidates

  • Mechanism of Action:

· T cell activation inhibitors
· Complement C5a inhibitors

  • Molecule Types:

· Monoclonal antibodies
· Recombinant fusion proteins

  • Route of Administration:

· Subcutaneous
· Intravenous

  • Product Types:

· Monotherapy
· Combination
· Mono/Combination

Key Questions regarding Current Granulomatosis With Polyangiitis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report

  • What are the current options for Granulomatosis With Polyangiitis treatment?

  • How many companies are developing therapies for the treatment of Granulomatosis With Polyangiitis?

  • How many are Granulomatosis With Polyangiitis emerging therapies in the early-stage, mid-stage, and late development stages to treat Granulomatosis With Polyangiitis?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Granulomatosis With Polyangiitis market?

  • Which are the dormant and discontinued products and the reasons for the same?

  • What is the unmet need for current therapies for the treatment of Granulomatosis With Polyangiitis?

  • What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Granulomatosis With Polyangiitis therapies?

  • What are the critical designations that have been granted for the emerging therapies for Granulomatosis With Polyangiitis?

  • How many patents are granted and pending for the emerging therapies to treat Granulomatosis With Polyangiitis?

Table of Contents

1

Granulomatosis With Polyangiitis Report Introduction

2

Granulomatosis With Polyangiitis Executive Summary

3

Granulomatosis With Polyangiitis Overview

4

Granulomatosis With Polyangiitis Pipeline Therapeutics

5

Granulomatosis With Polyangiitis Therapeutic Assessment

6

Granulomatosis With Polyangiitis – DelveInsight’s Analytical Perspective In-depth Commercial Assessment

7

Granulomatosis With Polyangiitis Late Stage Products (Phase III)

8

Granulomatosis With Polyangiitis Mid Stage Products (Phase II)

9

Granulomatosis With Polyangiitis Early Stage Products (Phase I)

10

Granulomatosis With Polyangiitis Preclinical and Discovery Stage Products

11

Granulomatosis With Polyangiitis Inactive Products

12

Granulomatosis With Polyangiitis Key Companies

13

Granulomatosis With Polyangiitis Key Products

14

Granulomatosis With Polyangiitis Unmet Needs

15

Granulomatosis With Polyangiitis Market Drivers and Barriers

16

Appendix

17

About DelveInsight

Get a customised pipeline report @ Granulomatosis With Polyangiitis Drugs Pipeline Report

Other Reports

Browse Blog Posts

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

CONTACT: Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com